These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32863284)

  • 1. Effect of Cetrorelix administration on ovarian stimulation in aged mice.
    Kanda A; Nobukiyo A; Sotomaru Y
    Exp Anim; 2021 Feb; 70(1):31-36. PubMed ID: 32863284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment.
    Roulier R; Chabert-Orsini V; Sitri MC; Barry B; Terriou P
    Reprod Biomed Online; 2003 Sep; 7(2):185-9. PubMed ID: 14567887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
    Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
    Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone-induced delayed ovulation affects early embryonic development.
    Bittner AK; Horsthemke B; Winterhager E; Grümmer R
    Fertil Steril; 2011 Jun; 95(7):2390-4. PubMed ID: 21474126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of GnRH antagonist cetrorelix on Wnt signaling members in pubertal and adult mouse ovaries.
    Tepekoy F; Uysal F; Acar N; Ustunel I; Akkoyunlu G
    Histochem Cell Biol; 2019 Dec; 152(6):423-437. PubMed ID: 31630211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
    Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
    Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
    Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
    Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols.
    Engel JB; Ludwig M; Junge K; Howles CM; Diedrich K
    Reprod Biomed Online; 2003 Jun; 6(4):482-7. PubMed ID: 12831598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
    Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
    Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of gonadotropin-releasing hormone antagonist in ovarian stimulation.
    Olivennes F
    Clin Obstet Gynecol; 2006 Mar; 49(1):12-22. PubMed ID: 16456339
    [No Abstract]   [Full Text] [Related]  

  • 12. Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.
    Ozelci R; Dilbaz S; Dilbaz B; Cırık DA; Yılmaz S; Tekin OM
    Taiwan J Obstet Gynecol; 2019 Mar; 58(2):234-238. PubMed ID: 30910145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.
    Felberbaum RE; Albano C; Ludwig M; Riethmüller-Winzen H; Grigat M; Devroey P; Diedrich K
    Hum Reprod; 2000 May; 15(5):1015-20. PubMed ID: 10783344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Revisiting the clomifene-gonadotropin protocol in IVF with the use of a GnRH antagonist].
    Emperaire JC; Parneix I; Perraguin-Jayot S
    Gynecol Obstet Fertil; 2003 Nov; 31(11):927-31. PubMed ID: 14623556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles.
    Lin YH; Seow KM; Hsieh BC; Huang LW; Chen HJ; Huang SC; Chen CY; Chen PH; Hwang JL; Tzeng CR
    J Assist Reprod Genet; 2007 Aug; 24(8):331-6. PubMed ID: 17636445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.
    Lee TH; Wu MY; Chen HF; Chen MJ; Ho HN; Yang YS
    Fertil Steril; 2005 Jun; 83(6):1700-7. PubMed ID: 15950639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The administration of the GnRH antagonist, cetrorelix, to ooctye donors simplifies oocyte donation.
    Thong KJ; Yong PY; Menezes Q
    Hum Reprod; 2003 Jun; 18(6):1256-8. PubMed ID: 12773455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.